Antineoplastic CP 868596 Crenolanib Inhibitor Cas 670220-88-9
Antineoplastic CP 868596 Crenolanib Inhibitor Cas 670220-88-9
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:CP-868596 Crenolanib |
Purity:98% min |
|
CAS NO:670220-88-9 |
Solubility22.2mg/mL in DMSO |
|
Molecular Formula:C26H29N5O2 |
Package:Package according to customer requirements |
|
Molecular Weight:443.541 |
Storage:Store at -20℃ |
Quality control
COA
Remarks
Crenolanib is a n orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation.
Related Products
Pexidartinib hcl; Pexidartinib; Telatinib; Avapritinib; Amuvatinib; DovitinibLactate; Linifanib; OSI-930; Motesanib Diphosphate; Motesanib; Sunitinib; Imatinib mesylate; Axitinib; Masitinib; Dovitinib; ISCK03
References
[1].Heinrich MC, et al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res, 2012, Jun 27.
[2].Mathias TJ, et al. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs. 2015 Apr;33(2):300-9.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.